# South Korea Biobanking Market > South Korea Biobanking Market Research Report By Sample Type (Blood Products, Tissues, Cells, Nucleic Acids, Microbiome Samples), By Application (Research and Development, Clinical Trials, Personalized Medicine, Regenerative Medicine), By End Use (Academic Research Institutions, Biotechnology Companies, Pharmaceutical Companies, Government Organizations) and By Storage Type (Vapor Phase Storage, Liquid Phase Storage, Cryopreservation Storage) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 4.12% - **2024:** $ 1,507.86 Million - **2025:** $ 1,569.98 Million - **2035:** $ 2,351 Million - **Key Players:** Thermo Fisher Scientific (US), Qiagen (NL), Illumina (US), Merck KGaA (DE), STEMCELL Technologies (CA), BioLife Sciences (US), ReproCELL (JP), Tecan Group (CH), Biosample Solutions (US) **Report ID:** MRFR/HC/52632-HCR · **Pages:** 200 · **Author:** Rahul Gotadki · **Last Updated:** February 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/south-korea-biobanking-market-54395 --- ## Market Summary ## **South Korea Biobanking Market Overview** As per MRFR analysis, the South Korea Biobanking Market Size was estimated at 98.6 (USD Million) in 2023.The South Korea Biobanking Market Industry is expected to grow from 102.8(USD Million) in 2024 to 250 (USD Million) by 2035. The South Korea Biobanking Market CAGR (growth rate) is expected to be around 8.414% during the forecast period (2025 - 2035). ## **Key South Korea Biobanking Market Trends Highlighted** The South Korea Biobanking Market is growing quickly because of new developments in biotechnology and a growing need for precision medicine. The South Korean government has been putting money into biobanking infrastructure to make it easier to collect and store biological samples. This is part of their focus on research and development. This stimulates collaboration between academic institutions, hospitals, and biotech enterprises, which plays a critical role in developing the biobanking ecosystem.  Combining artificial intelligence with big data analytics is changing how samples are handled and analysed, which leads to more personalized healthcare treatments. There are a lot of chances in the South Korea Biobanking Market because chronic diseases are becoming more common and there is a need for a lot of genetic research.  As personalized therapy becomes more important in healthcare, biobanks that can provide well-defined biological resources will be in great demand. Korea's robust rules for biobanks also follow global standards, which helps build international alliances and bring in foreign investment.  More people are becoming aware of how important biobanking is, which is also a chance to get more people involved and support from the community. Recent trends show that biobanking is moving toward more ethical methods because of changes in the law and what people want. South Korea is putting informed consent and data privacy first to protect the rights of participants and build trust in the system. The country is a member of worldwide biobanking networks, which makes it easier for researchers to work together and exchange resources and results.  To meet the increased demand for competent workers in this industry, programs are now being created to teach and train biobanking experts. The South Korean Biobanking Market is likely to keep growing because of new technologies, ethical concerns, and public interest. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **South Korea Biobanking Market Drivers** **Rising Demand for Personalized Medicine** The South Korea Biobanking Market Industry is experiencing significant growth due to the rising demand for personalized medicine. With the increasing focus on patient-centric healthcare, the demand for biobanks to provide genetic data for personalized treatment plans has escalated. According to the South Korean government, the personalized medicine sector is projected to grow by over 10% annually, with advancements in genomics and biotechnology fueling innovations.Organizations such as the Korea National Biobank have been instrumental in collecting and storing biological samples that aid in Research and Development for personalized therapies, thereby enhancing the accessibility of targeted treatment solutions for various diseases such as cancer and cardiovascular conditions. **Growing Investment in Biotechnology and Genomic Research** In South Korea, substantial investment in biotechnology and genomic research catalyzes the growth of the South Korea [Biobanking](../../../reports/biobanking-market-5967) Market Industry. The South Korean government announced a robust investment strategy in biotechnology, amounting to approximately 2 billion USD over the next five years, aiming to bolster Research and Development activities across the sector.  This influx of capital is anticipated to not only enhance biobanking infrastructure but also facilitate the creation of advanced biobanks that support extensive genomic research.Notable institutions like the Korea Institute of Science and Technology are at the forefront of these initiatives, promoting innovation and development in biobanking applications. **Increasing Prevalence of Chronic Diseases** The increasing prevalence of chronic diseases, such as diabetes and cancer, significantly drives the South Korea Biobanking Market Industry. According to the Korean National Health Insurance Service, cancer incidence rates have risen substantially, with an estimated 250,000 new cancer cases recorded annually.  This alarming trend necessitates the establishment of biobanks that can provide high-quality biological samples for research aimed at understanding disease mechanisms and developing new treatments.As medical research continues to evolve, organizations like the Korean Cancer Association have begun collaborating with biobanks to better utilize these resources for disease prevention and management strategies. **Advancements in Laboratory Technology and Data Management** Technological advancements in laboratory equipment and data management systems play a crucial role in the growth of the South Korea Biobanking Market Industry. Innovative solutions in specimen processing, storage, and retrieval have streamlined biobanking operations, making them more efficient and reliable.  The introduction of automated systems and improved bioinformatics tools facilitates better data collection and analysis, leading to enhanced research outcomes.According to a report by the Korean Society for Biochemistry and Molecular Biology, these advancements have led to a 50% increase in sample processing capacity in leading biobanks across the region, thus catering to the growing demand for biobank services. ## **South Korea Biobanking Market Segment Insights** ### **Biobanking Market Sample Type Insights** The South Korea Biobanking Market has a lot of different parts, especially in the Sample Type category, which is quite important for how biobanks work as a whole. In this area, a wide range of biological samples are gathered and stored. These samples are very important for research and development, diagnostics, and personalized therapy.  Blood products make up a large part of this market since they can be used in many different ways, such as in transfusions and as the basis for many clinical research investigations.  Tissues taken from different origins help scientists learn more about how cells interact with one other and make progress in regenerative medicine and cancer research. Also, cells, especially stem cells, are being used to treat a wide range of disorders, which increases their need in this area. DNA and RNA are examples of nucleic acids that are very important for genetic research.  They have led to advances in gene therapy and tailored treatment strategies. Researchers are also looking into microbiome samples to learn more about the close link between human health and microbial ecosystems. This is a new area of research in personalized medicine.  The South Korean biobanking market has been moving toward these types of samples over time. This is because the government has been pushing for biobanks to be more important in healthcare innovation.This part of the market is set to increase a lot because of improvements in storage technology and more partnerships between biotech businesses and academic institutions.  This is in line with worldwide trends in precision medicine and diagnostics. Different types of samples are important in different areas of research, showing how biobanking is important for improving treatment solutions. As biobanks in South Korea continue to grow, it is important to combine these sample types in order to make scientific discoveries and improve patient outcomes. **S****ource: Primary Research, Secondary Research, MRFR Database and Analyst Review** ### **Biobanking Market Application Insights** The Application segment of the South Korea Biobanking Market plays a crucial role in advancing healthcare and medical research within the region. This segment is primarily driven by factors such as increasing investments in Research and Development, which significantly enhances the understanding of diseases and the development of innovative treatments.  Clinical Trials benefit immensely from biobanking, as access to diverse biological samples aids in producing more effective and targeted therapies. Personalized Medicine is gaining traction, as it leverages biobanked samples to tailor treatments individually, improving patient outcomes and satisfaction. Additionally, Regenerative Medicine is emerging as a vital area, utilizing biobanked cells and tissues for innovative therapies that restore or replace damaged tissues and organs. The overall growth in the South Korea Biobanking Market is supported by a robust healthcare framework, government initiatives promoting research, and collaboration among institutions, making it a significant contributor to advancements in medical science.  The potential for innovation in this area presents various opportunities, including enhanced patient care, improved diagnostic tools, and the development of cutting-edge therapies that address unmet medical needs. ### **Biobanking Market End Use Insights** The South Korea Biobanking Market is witnessing significant growth across its End Use segment, which encompasses a variety of critical players such as Academic Research Institutions, Biotechnology Companies, Pharmaceutical Companies, and Government Organizations. Academic Research Institutions represent a substantial part of this market, as they engage in extensive studies that often require vast biobanked samples, driving advancements in genomics and personalized medicine.  Biotechnology Companies are equally vital, utilizing biobanks to facilitate the development of novel therapeutics and diagnostic tools, thereby enhancing innovation.Pharmaceutical Companies leverage biobanks for Research and Development purposes, which allows them to conduct clinical trials more effectively by accessing a rich diversity of biological samples.  Government Organizations play a crucial role by providing regulatory frameworks that support biobanking initiatives, which helps in promoting ethical standards while securing funding for research projects. The interplay among these segments contributes to the overall South Korea Biobanking Market revenue, positioning the country as a leader in biobanking within the region. The increasing focus on precision medicine and the growing need for data-driven approaches in healthcare are driving opportunities for growth and collaboration among these entities. As a result, the South Korea Biobanking Market segmentation continues to evolve, reflecting the diverse interests and needs of stakeholders involved in biobanking activities. ### **Biobanking Market Storage Type Insights** The Storage Type segment of the South Korea Biobanking Market plays a crucial role in preserving biological samples, which is pivotal for research and diagnostics. Within this segment, Vapor Phase Storage is significant due to its ability to maintain samples at ultra-low temperatures, minimizing cellular damage and maximizing sample integrity.  Liquid Phase Storage also holds importance, particularly for tissues and other biological materials that require precise temperature control to remain viable over time.  Cryopreservation Storage dominates in the biobanking sector since it facilitates long-term storage of cells, tissues, and even embryos, which is essential for regenerative medicine and fertility treatments.The advancements in storage technologies have further propelled the growth of this segment, aligning with the increasing emphasis on personalized medicine and Research and Development initiatives in South Korea's healthcare industry.  As the demand for biological samples continues to rise, driven by trends in genomics and proteomics, the Storage Type segment is set to gain a larger share of the South Korea Biobanking Market, supporting the overall market growth and contributing to significant advancements in medical research and innovation. **South Korea Biobanking Market Key Players and Competitive Insights** The South Korea Biobanking Market is growing quickly because of new developments in biotechnology, a growing need for tailored medication, and a greater focus on research and development. There are many different types of companies in the competitive landscape, from big multinationals to small, specialized startups.  Companies in this sector are working hard to build strong biobanking systems that make it easier to collect, store, and share biological samples for research. As biotechnology continues to grow, the biobanking industry is expected to improve its services and make its operations more efficient.  This will create new chances for market participants to work together and come up with new ideas. The industry is much more competitive now that genomics and biotechnology technologies have improved. This has led to more investments and partnerships that are meant to speed up research projects and clinical applications.  Kgenics is a leader in the South Korean biobanking market since it focuses so much on genomic analysis and tailored therapy. The organization has built a strong infrastructure for collecting and managing biological samples, which makes it easy for academics and healthcare practitioners to get high-quality samples for their studies.  Kgenics wants to make the best use of biobanks in many scientific domains by using cutting-edge technology. This makes it a good choice for researchers looking for reliable sample sources. The company has formed strategic connections with research organizations and academic institutions, which has helped it become more well-known and solidify its place in the biobanking ecosystem in South Korea. Kgenics’ continual investment in technological improvements and collaboration reinforces its competitive position as a vital participant in the local industry.  MedRex is another important player in the South Korea Biobanking Market. It focuses on storing and managing biological samples for a variety of research purposes. The organization provides comprehensive services, including sample collection, processing, and distribution, which are crucial for clinical trials and other research endeavours. MedRex has formed strategic agreements with a number of healthcare and research organizations, which has helped it grow in the biobanking field.  The organization is known for its dedication to quality and following the rules, which makes sure that the samples it handles are of the greatest quality. MedRex is also actively involved in mergers and acquisitions, which helps it reach its growth goals and strengthens its presence in the South Korean market. As the biobanking industry changes, MedRex's focus on high-quality sample management and partnerships puts it in a good position to take advantage of new opportunities in the fast-growing healthcare and research markets. **Key Companies in the South Korea Biobanking Market Include:** - Kgenics - MedRex - Celltrion - MediGene - Sangamo Therapeutics - Biogen - Genexine - Green Cross Corporation - Korea Research Institute of Bioscience and Bioengineering - HumGenome - [Theragen Etex](http://www.theragenetex.com/) - Cure Genetics - Sooam Biotech Holdings - Hanlim Pharm - Korea National Corporation **South Korea Biobanking Market Industry Developments** Recent developments in the South Korea Biobanking Market indicate significant growth and innovations. Companies such as Kgenics and MedRex are advancing their biobanking technologies, enhancing the quality of biological samples for research and clinical applications. In September 2023, Celltrion announced an expansion of its biobank facilities to accommodate an increase in demand for cell and gene therapies, representing an investment in developing personalized medicine strategies.  Sangamo Therapeutics has been focusing on collaborations aimed at using its gene-editing technology for therapeutic development, thereby enhancing its biobanking capabilities. Furthermore, in August 2022, Biogen established a partnership with Theragen Etex to introduce precision medicine solutions utilizing advanced biobanking practices. Green Cross Corporation has recently invested in R&D to leverage biobanks for vaccine development, showcasing a heightened focus on public health.  Growth in market valuations across these companies is underpinned by rising investments in biobanking for therapeutic advancements, with expectations of increased government support through initiatives from the Korea Research Institute of Bioscience and Bioengineering. Over the past few years, key events like the establishment of new biobanking regulations in March 2021 have also fostered a conducive environment for research and innovation within this market. ## **South Korea Biobanking Market Segmentation Insights** ### **Biobanking Market Sample Type Outlook** - Blood Products - Tissues - Cells - Nucleic Acids - Microbiome Samples ### **Biobanking Market Application Outlook** - Research and Development - Clinical Trials - Personalized Medicine - Regenerative Medicine ### **Biobanking Market End Use Outlook** - Academic Research Institutions - Biotechnology Companies - Pharmaceutical Companies - Government Organizations ### **Biobanking Market Storage Type Outlook** - Vapor Phase Storage - Liquid Phase Storage - Cryopreservation Storage ## Market Drivers ### Supportive Government Policies The South Korean government is actively promoting biobanking initiatives, which is a key driver for the biobanking market. Policies aimed at enhancing research capabilities and funding for biobanks are being implemented. For example, the government has allocated substantial resources to support biobanking infrastructure and research projects. This support is crucial for fostering innovation and collaboration within the sector. As a result, the biobanking market is expected to benefit from increased investment and improved regulatory frameworks that facilitate research and development. ### Emerging Research Opportunities The biobanking market in South Korea is experiencing growth due to emerging research opportunities in various fields, including genomics, proteomics, and personalized medicine. Researchers are increasingly relying on biobanks to access high-quality biological samples for their studies. This trend is likely to expand as new research initiatives are launched, particularly in areas such as cancer research and rare diseases. The demand for diverse biological samples is expected to drive the market, with projections indicating a potential increase in market size by over 15% in the coming years. ### Advancements in Biobanking Technologies Technological innovations are significantly impacting the biobanking market in South Korea. The introduction of automated sample processing and advanced storage solutions enhances the efficiency and reliability of biobanks. For instance, the integration of artificial intelligence in data management systems allows for better sample tracking and analysis. As a result, biobanks can offer more comprehensive services to researchers and healthcare institutions. The market is projected to grow at a CAGR of around 10% over the next five years, driven by these technological advancements that improve operational capabilities and data integrity. ### Rising Demand for Personalized Medicine The increasing focus on personalized medicine is driving the biobanking market in South Korea. As healthcare shifts towards tailored treatments, the need for biobanks to store diverse biological samples becomes crucial. This trend is reflected in the growing investment in biobanking facilities, with estimates suggesting that the market could reach approximately $1.5 billion by 2027. Personalized medicine relies heavily on genetic and molecular data, which biobanks provide. Consequently, the biobanking market is likely to expand as healthcare providers seek to enhance patient outcomes through customized therapies. ### Growing Public Awareness and Participation Public awareness regarding the importance of biobanking is increasing in South Korea, which is positively influencing the biobanking market. Educational campaigns and community outreach programs are encouraging individuals to donate biological samples for research purposes. This heightened awareness is expected to lead to a larger pool of samples available for research, thereby enhancing the quality of studies conducted. As participation rates rise, biobanks are likely to see an increase in funding and support from both governmental and private sectors, further propelling market growth. ## Future Outlook The [Biobanking Market](https://www.marketresearchfuture.com/reports/biobanking-market-5967) in South Korea is projected to grow at a 4.12% CAGR from 2025 to 2035, driven by advancements in personalized medicine, increased research funding, and technological innovations. **New opportunities:** - Development of automated biorepository management systems Expansion of partnerships with pharmaceutical companies for clinical trials Investment in advanced cryopreservation technologies for sample integrity By 2035, the biobanking market is expected to achieve robust growth and enhanced operational efficiencies. ## Segment Insights ### By Sample Type: Blood Products (Largest) vs. Tissues (Fastest-Growing) In the South Korea biobanking market, the distribution of sample types shows that blood products occupy the largest segment, reflecting their critical role in diagnostics and therapeutic applications. Tissues, while smaller in market share, are emerging as a significant contributor due to their increasing utilization in regenerative medicine and cancer research. Growth trends indicate that the demand for tissues is increasing rapidly, driven by advancements in biobanking technology and the integration of personalized medicine approaches. Blood products continue to maintain a dominant position, supported by their widespread use in clinical settings. The overall market dynamics suggest a trend towards diversification in sample types as researchers seek to optimize their biobanking strategies for various applications. Blood Products (Dominant) vs. Tissues (Emerging) Blood products are a dominant force in the South Korea biobanking market, primarily due to their extensive application in transfusion medicine, diagnostics, and therapeutic development. Their stable demand is driven by the ongoing needs for blood transfusions and related therapies. In contrast, tissues are emerging as a vital segment, propelled by advancements in technologies such as tissue engineering and regenerative medicine. Researchers are increasingly focusing on the collection, preservation, and application of tissue samples to understand disease mechanisms and develop novel treatments. This shift highlights the evolving landscape of biobanking, where both blood products and tissues play crucial roles, reflecting the market's adaptability and innovation potentials. ### By Application: Personalized Medicine (Largest) vs. Clinical Trials (Fastest-Growing) In the South Korea biobanking market, the Application segment reveals a diverse allocation of market share among its values. Personalized Medicine captures the largest share, driven by the increasing demand for tailored healthcare solutions. Research and Development follows closely, supported by significant investments in biotechnology. Although Clinical Trials represent a smaller fraction, their share is significantly rising due to the robust growth of pharmaceutical research focused on innovative therapies. The growth trends within this segment are marked by rapid advancements in technology and a shift toward precision medicine. The emphasis on patient-centric approaches and the burgeoning field of regenerative medicine are key drivers behind the dynamic expansion of Clinical Trials. This market is poised for substantial growth as regulatory frameworks adapt to support new therapeutic developments, ultimately enhancing the bioethical landscape of medical research. Personalized Medicine (Dominant) vs. Clinical Trials (Emerging) Personalized Medicine stands as the dominant force in the Application segment due to its role in delivering customized healthcare solutions based on individual patient profiles. This approach facilitates more effective treatment plans, aligning with the contemporary shift toward tailored medicine. On the other hand, Clinical Trials are emerging as a critical component of pharmaceutical development in the South Korea biobanking market, reflecting an increasing focus on innovative therapies and the need for effective clinical validation. The growing reliance on Clinical Trials for drug approvals and the exploration of novel therapeutic agents also highlights the market's transition towards more personalized and validated healthcare solutions. As both segments evolve, they are likely to influence the future landscape of medical research and treatment methodology. ### By End-use: Pharmaceutical Companies (Largest) vs. Biotechnology Companies (Fastest-Growing) In the South Korea biobanking market, the distribution of market share among key end-use segments shows that pharmaceutical companies hold the largest share. This segment is heavily weighted due to their reliance on biobanks for drug discovery, development, and clinical trials. Academic research institutions also play a significant role, although they follow behind in market share. Government organizations are crucial as they support initiatives and funding but contribute less to the overall market dynamics. The growth trends within this segment indicate that biotechnology companies are currently the fastest-growing end-users. Their rise is driven by increased investments in research and development as well as advancements in biotechnological applications. Additionally, collaborations and partnerships with academic institutions and government bodies further propel growth. The evolving landscape of personalized medicine and innovative therapeutic solutions is likely to enhance the demand for biobanking services among these emerging players. Pharmaceutical Companies (Dominant) vs. Biotechnology Companies (Emerging) Pharmaceutical companies dominate the South Korea biobanking market, leveraging biobanks for extensive research purposes and the development of new therapeutics. Their established infrastructure and significant financial resources allow them to utilize biobanks extensively for clinical trials and regulatory compliance. In contrast, biotechnology companies are marking their presence as emerging players in this sector. They capitalize on cutting-edge technology and innovative approaches to utilize biobanking resources effectively. Their focus on niche markets and personalized medicine solutions strengthens their position, and as they expand their functionalities, they are likely to become increasingly significant competitors in the biobanking ecosystem. ### By Storage Type: Liquid Phase Storage (Largest) vs. Cryopreservation Storage (Fastest-Growing) In the South Korea biobanking market, the distribution of market share among storage types highlights Liquid Phase Storage as the largest segment, accounting for a significant portion of the market. Vapor Phase Storage follows, though it holds a smaller share compared to its counterparts. The delineation between these storage types reveals a strategic focus on optimizing biological sample preservation, which directly influences biobank operational efficiency and reliability. Growth trends for the storage segment suggest a robust demand for Cryopreservation Storage, which is emerging as the fastest-growing storage method due to its advantages in preserving sensitive biological samples over extended periods. Factors contributing to this growth include advancements in cryoprotectants and container technology, which enhance storage capabilities and reduce sample degradation risks, further propelled by increasing biobanking activities and research initiatives in biotechnology and personalized medicine. Liquid Phase Storage (Dominant) vs. Cryopreservation Storage (Emerging) Liquid Phase Storage is recognized in the South Korea biobanking market as the dominant method, appreciated for its efficient management of biological samples. This storage technique enables prolonged preservation by maintaining samples in a controlled, low-temperature environment. In contrast, Cryopreservation Storage is emerging rapidly, gaining traction among biobanks for its ability to minimize cellular damage during preservation. The use of Cryopreservation techniques is supported by increasing public and private investments in biobanks that aim to foster innovation in life sciences. Both storage methods exhibit unique benefits and align with the growing need for reliable, long-term storage solutions in biobanking, positioning them as vital components in advancing healthcare and research capabilities. ## Competitive Benchmarking The biobanking market in South Korea is characterized by a dynamic competitive landscape, driven by advancements in biotechnology and increasing demand for personalized medicine. Key players such as Thermo Fisher Scientific (US), Qiagen (NL), and Illumina (US) are at the forefront, leveraging their extensive portfolios to enhance operational capabilities. Thermo Fisher Scientific (US) focuses on innovation through continuous investment in R&D, while Qiagen (NL) emphasizes strategic partnerships to expand its market reach. Illumina (US) is known for its cutting-edge sequencing technologies, which are pivotal in biobanking applications. Collectively, these strategies foster a competitive environment that is increasingly oriented towards technological advancement and collaborative growth.In terms of business tactics, companies are localizing manufacturing and optimizing supply chains to enhance efficiency and reduce costs. The market structure appears moderately fragmented, with several players vying for market share. However, the influence of major companies is substantial, as they set industry standards and drive innovation. This competitive structure encourages smaller firms to adopt niche strategies or seek partnerships to remain relevant in the evolving landscape. In October Thermo Fisher Scientific (US) announced the launch of a new biobanking solution aimed at improving sample preservation and data management. This strategic move is significant as it aligns with the growing emphasis on data integrity and sample quality in biobanking, potentially enhancing the company's competitive edge in the market. By addressing these critical needs, Thermo Fisher Scientific (US) positions itself as a leader in biobanking solutions, catering to the demands of research institutions and healthcare providers. In September Qiagen (NL) expanded its collaboration with a leading South Korean university to develop advanced genomic analysis tools for biobanking applications. This partnership is indicative of Qiagen's strategy to integrate local expertise and resources, thereby enhancing its product offerings. Such collaborations not only strengthen Qiagen's market presence but also facilitate the development of tailored solutions that meet specific regional needs, thereby fostering innovation in the biobanking sector. In August Illumina (US) unveiled a new platform designed to streamline the biobanking process, integrating AI-driven analytics for better sample tracking and management. This initiative reflects a broader trend towards digitalization within the industry, as companies seek to leverage technology to improve operational efficiency. By adopting AI solutions, Illumina (US) enhances its value proposition, making it a formidable competitor in the biobanking market. As of November current trends in the biobanking market include a pronounced shift towards digitalization, sustainability, and AI integration. Strategic alliances are increasingly shaping the competitive landscape, enabling companies to pool resources and expertise. Looking ahead, competitive differentiation is likely to evolve, with a focus on innovation and technology rather than price-based competition. Companies that prioritize supply chain reliability and technological advancements will likely emerge as leaders in this rapidly changing environment. ## Recent News & Developments Recent developments in the South Korea Biobanking Market indicate significant growth and innovations. Companies such as Kgenics and MedRex are advancing their biobanking technologies, enhancing the quality of biological samples for research and clinical applications. In September 2023, Celltrion announced an expansion of its biobank facilities to accommodate an increase in demand for cell and gene therapies, representing an investment in developing personalized medicine strategies.  Sangamo Therapeutics has been focusing on collaborations aimed at using its gene-editing technology for therapeutic development, thereby enhancing its biobanking capabilities. Furthermore, in August 2022, Biogen established a partnership with Theragen Etex to introduce precision medicine solutions utilizing advanced biobanking practices. Green Cross Corporation has recently invested in R&D to leverage biobanks for vaccine development, showcasing a heightened focus on public health.  Growth in market valuations across these companies is underpinned by rising investments in biobanking for therapeutic advancements, with expectations of increased government support through initiatives from the Korea Research Institute of Bioscience and Bioengineering. Over the past few years, key events like the establishment of new biobanking regulations in March 2021 have also fostered a conducive environment for research and innovation within this market. ## Report Scope | MARKET SIZE 2024 | 1507.86(USD Million) | | --- | --- | | MARKET SIZE 2025 | 1569.98(USD Million) | | MARKET SIZE 2035 | 2351.0(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 4.12% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Thermo Fisher Scientific (US), Qiagen (NL), Illumina (US), Merck KGaA (DE), STEMCELL Technologies (CA), BioLife Sciences (US), ReproCELL (JP), Tecan Group (CH), Biosample Solutions (US) | | Segments Covered | Sample Type, Application, End-use, Storage Type | | Key Market Opportunities | Advancements in personalized medicine drive demand for innovative biobanking solutions in South Korea. | | Key Market Dynamics | Growing demand for personalized medicine drives innovation and competition in the biobanking market. | | Countries Covered | South Korea | ## Frequently Asked Questions **Q: What is the current valuation of the biobanking market in South Korea?** A: The biobanking market was valued at $1507.86 Million in 2024. **Q: What is the projected market valuation for South Korea's biobanking sector by 2035?** A: The market is projected to reach $2351.0 Million by 2035. **Q: What is the expected CAGR for the South Korea biobanking market from 2025 to 2035?** A: The expected CAGR during the forecast period 2025 - 2035 is 4.12%. **Q: Which sample type segment has the highest valuation in the South Korea biobanking market?** A: The Nucleic Acids segment had a valuation of $400.0 Million in 2024 and is expected to grow significantly. **Q: What are the key applications driving growth in the South Korea biobanking market?** A: Personalized Medicine, with a valuation of $450.0 Million in 2024, is a key application driving growth. **Q: Which end-use segment contributed the most to the biobanking market in South Korea?** A: Pharmaceutical Companies contributed the most, with a valuation of $500.0 Million in 2024. **Q: What storage type segment is expected to see the most growth in the South Korea biobanking market?** A: Cryopreservation Storage, valued at $707.86 Million in 2024, is expected to see substantial growth. **Q: Who are the leading players in the South Korea biobanking market?** A: Key players include Thermo Fisher Scientific, Qiagen, Illumina, and Merck KGaA. **Q: What was the valuation of the Clinical Trials application segment in 2024?** A: The Clinical Trials application segment was valued at $400.0 Million in 2024. **Q: How does the valuation of the Tissues segment compare to the Microbiome Samples segment?** A: The Tissues segment was valued at $250.0 Million, while the Microbiome Samples segment was valued at $357.86 Million in 2024. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/south-korea-biobanking-market-54395*